NHS plans free pharmacy cholesterol checks across England

High cholesterol and high blood pressure are risk factors for cardiovascular disease, but they may not be apparent without measurement. Offering both checks at a pharmacy gives eligible people another route to learn their results and discuss them with a prescriber, rather than relying solely on a GP-based blood test. For those whose results indicate elevated risk, the model links screening to an immediate clinical conversation and possible referral or treatment assessment. That connection is important because a test alone does not reduce risk; any benefit depends on follow-up care and on patients being able to act on advice or prescribed treatment.

The policy is part of the NHS’s stated effort to bring some care previously provided in GP surgeries closer to where people live. Pharmacies are being used not simply as testing sites: the proposed service includes immediate analysis, a blood-pressure measurement and consultation with a pharmacist prescriber. The north London pilot supplies early operational evidence for that model, with 2,493 checks completed and 19% of participants identified as at high risk over the next decade. However, those figures describe one pilot population and do not establish how many people nationally will use the service, how representative participants were, or whether the same risk-detection rate will occur across England.

The reported pilot gives a basis for expansion, but it has clear limits as evidence of national outcomes. The article does not state when the pilot ran, how participants were recruited, the number referred who completed treatment, or whether statin use and risk-factor control persisted after the consultation. It also reports people assessed as high risk, rather than subsequent reductions in heart attacks or strokes. The precise list of participating pharmacies, local availability, funding arrangements and the criteria pharmacists will use to refer patients are not provided, leaving important implementation questions unresolved.

About 100 pharmacies are expected to start the first phase this autumn. Useful next evidence would include the participating locations, uptake among eligible people, referral completion, treatment starts, and whether the NHS publishes outcome data beyond the north London pilot.